Please login to the form below

Not currently logged in
Email:
Password:

Eyevensys

This page shows the latest Eyevensys news and features for those working in and with pharma, biotech and healthcare.

Spark set to file eye disease gene therapy next year

Spark set to file eye disease gene therapy next year

Others include Bristol-Myers Squibb-backed Eyevensys, GenSight Biologics (supported by Novartis), Oxford Biomedica, Avalanche Biotechnologies, Applied Genetic Technologies, and ReGenxbio.

Latest news

  • Boehringer backs gene therapy firm Eyevensys Boehringer backs gene therapy firm Eyevensys

    Boehringer Ingelheim has announced an equity investment in French gene therapy firm Eyevensys, which specialises in the treatment of eye diseases. ... Eyevensys was set up in 2009 and raised 1.6m in its first financing round in early 2012.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics